News Releases | Charles River Laboratories International, Inc.
Sep 4, 2024 · Charles River Laboratories Announces Strategic Lentiviral Vector Manufacturing Collaboration with Gates Institute at University of Colorado Anschutz Medical Campus. 06/17/24. Charles River and Captain T Cell Announce Plasmid DNA and Viral Vector Manufacturing Alliance for Gene-Modified Cell Therapy. 06/11/24.
Investor Relations - Charles River Laboratories International, Inc.
May 11, 2023 · WILMINGTON, Mass. -- (BUSINESS WIRE)--May 11, 2023-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of …
Charles River Laboratories Announces First-Quarter 2022 Results
May 4, 2022 · Organic revenue growth of 10.1% was driven by strong demand for Biologics Testing Solutions services, with Microbial Solutions revenue also increasing. In the first quarter of 2022, the Manufacturing segment’s GAAP operating margin decreased to 24.0% from 33.8% in the first quarter of 2021.
Investor Relations - Charles River Laboratories International, Inc.
Dec 31, 2020 · The acquisition of Distributed Bio expands Charles River’s scientific capabilities with an innovative, large-molecule discovery platform. The transaction combines Distributed Bio’s antibody libraries and immuno-engineering platform with Charles River’s extensive drug discovery and non-clinical development expertise to create an integrated ...
Investor Relations - Charles River Laboratories International, Inc.
Feb 16, 2022 · Revenue for the DSA segment was $534.1 million in the fourth quarter of 2021, an increase of 7.9% from $495.0 million in the fourth quarter of 2020. The impact of foreign currency translation reduced revenue by 0.4%, and acquisitions contributed 1.6% to DSA revenue growth.
Charles River Laboratories to Present at Barclays Global Healthcare ...
Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com .
Charles River Laboratories Plans to Increase CRADL Capacity in ...
To further support the Cambridge biohub, Charles River is expanding locally, including the second phase of its multi-year expansion program that begun in 2021, increasing capacity for contract breeding and housing of genetically modified colonies in Wilmington, Massachusetts.
Charles River Laboratories Announces Third-Quarter 2023 Results
Nov 8, 2023 · WILMINGTON, Mass. -- (BUSINESS WIRE)--Nov. 8, 2023-- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2023. For the quarter, revenue was $1.03 billion, an increase of 3.8% from $989.2 million in the third quarter of 2022.
Feb 14, 2024 · On November 30, 2023, Charles River Laboratories completed the acquisition of an additional 41% equity stake of Noveprim Group, a Mauritius-based provider of non-human primates (NHPs) for regulatory required biomedical, …
Charles River Announces Rare Disease Gene Therapy Collaboration …
Apr 9, 2024 · Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the development of Axovia’s gene therapies for ciliopathies, including Bardet-Biedl Syndrome (BBS), a condition with limited treatment options and no cure.